Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene amplified solid tumors.
Lead Product(s): BBI-355,Futibatinib
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Boundless Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2023
Details:
TAS6417 (zipalertinib) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was engineered to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR.
Lead Product(s): CLN-081,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: TAS6417
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
Lonsurf (trifluridine/tipiracil), an oral nucleoside antitumor agent, got approved as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC).
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.
Lead Product(s): Futibatinib
Therapeutic Area: Oncology Product Name: Lytgobi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2023
Details:
TAS-120 (futibatinib) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarcinoma
Lead Product(s): Futibatinib
Therapeutic Area: Oncology Product Name: TAS-120
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
Lonsurf consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, it has demonstrated anti-tumor activity against refractory colorectal cancer, in combination with bevacizumab.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations.
Lead Product(s): Futibatinib
Therapeutic Area: Oncology Product Name: Lytgobi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Lonsurf is an oral nucleoside antitumor agent which consists trifluridine, and tipiracil (TP inhibitor), which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine results in DNA dysfunction and inhibition of cell proliferation.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Servier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Lonsurf (trifluridine) and tipiracil consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Servier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Key presentations include: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Acquired resistance to ATP-competitive and irreversible FGFR inhibitors, etc.
Lead Product(s): Futibatinib
Therapeutic Area: Oncology Product Name: TAS-120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2021